FindTrial
Sign In

Clinical application of take oral meglumine esophagogram in screening esophageal fistula during radiotherapy for esophageal cancer

Clinical application of take oral meglumine esophagogram in screening esophageal fistula during radiotherapy for esophageal cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-DDD-17012617
Enrollment
Unknown
Registered
2017-09-07
Start date
2017-10-01
Completion date
Unknown
Last updated
2017-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esophageal cancer

Interventions

Gold Standard:Barium meal radiography
Esophagofiberoscope
CT examination
Index test:Take&#32
oral&#32
76%&#32
Meglumine&#32
Diatrizoate&#32
Injection&#32
about&#32
60ml&#32
and&#32
X-ray&#32
radiography

Sponsors

Mianyang Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Pathologically proved and inoperable I-IV - stage primary esophageal carcinoma, esophageal lesions were treated with radical IMRT, and patients or their families sign formal informed consent

Exclusion criteria

Exclusion criteria: Iodine allergy, hepatic and renal dysfunction, combined with active tuberculosis, multiple spinal tumors, hyperthyroidism, patients who fail to understand the requirements of the trial, or may not comply with the test requirements

Design outcomes

Primary

MeasureTime frame
esophageal fistula;—

Countries

China

Contacts

Public ContactDuxiaobo

Mianyang Central Hospital

duxiaobo2005@126.com+86 13550822229

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 17, 2026